Fangzhou Inc. Revolutionizes Healthcare with AI Innovation

Fangzhou Inc., a trailblazer in the realm of Internet healthcare solutions, has once again cemented its position as a leader in the industry. The company has been named to the 2024 Guangzhou Artificial Intelligence Innovation Development List as the "Most Promising Enterprise," while its H2H Smart Healthcare Ecosystem secured a spot on the "Application Scenario Innovation List" as a Top 10 AI+Healthcare Case. This recognition, issued by the Guangzhou Municipal Science and Technology Bureau, underscores Fangzhou's groundbreaking innovations in technology and its leadership in transforming the digital healthcare industry.

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, "Being recognized among Guangzhou's top AI innovators reflects Fangzhou's success in developing practical and scalable AI solutions for healthcare. This achievement reinforces our commitment to advancing an intelligent healthcare ecosystem that improves efficiency and accessibility."



Fangzhou's strategic collaboration with Tencent Health and Tencent Cloud has been a game-changer. The company has deepened its partnership to accelerate AI-driven healthcare solutions, integrating the open-source DeepSeek-V3 and DeepSeek-R1 models into its platform. Following the local deployment of DeepSeek's large language model in February, the partnership leverages Tencent's cloud infrastructure to power Fangzhou's upgraded "AI Agent 2.0" platform. This platform targets transformative applications in pharmaceutical logistics and healthcare services, enhancing efficiency and accessibility in these areas.

The H2H Smart Healthcare Ecosystem features four core AI modules: AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant. These tools are designed to streamline operations across the platform, from diagnostics to supply chain management, while improving patient and customer experiences. For instance, the AI Physician Assistant can assist doctors in making more accurate diagnoses, while the AI Customer Engagement Assistant can provide personalized support to patients, enhancing their overall experience.

Fangzhou's financial performance in 2024 has been nothing short of impressive. The company reported a revenue of RMB 2.7 billion for the fiscal year 2024, marking an 11.2% increase from the previous year. The adjusted net profit soared by 139%, reaching RMB 17.2 million. This growth is a testament to the company's commitment to technological advancement and operational efficiency. Fangzhou's physician network is another pillar of its success. The company expanded its registered physician base to 223,000, with a significant portion affiliated with Class III hospitals. This expansion is crucial as it enhances the quality of care and ensures that patients receive expert guidance.

Fangzhou's online retail pharmacy services saw an 8.3% revenue increase, reaching RMB 1.405 billion. Customized content and marketing solutions also grew by 20.7%. These figures illustrate Fangzhou's diverse revenue streams and its ability to adapt to market demands. The company collaborates with over 1,500 suppliers and more than 900 pharmaceutical companies. This extensive network allows Fangzhou to offer nearly 215,000 drug SKUs, with a significant portion being prescription drugs. Such a robust supply chain is vital for ensuring that patients have access to the medications they need.

Looking ahead, Fangzhou is not resting on its laurels. The company has set its sights on 2025 with a multi-faceted strategy. Key priorities include enhancing AI capabilities, improving user experience, and optimizing supply chain operations. Talent acquisition will also play a crucial role in driving innovation and growth.

In a bold move, Fangzhou recently partnered with Tencent Health and Tencent Cloud to accelerate the development of AI-enabled healthcare services. This collaboration aims to integrate the DeepSeek open-source AI model into Fangzhou’s platform. The upgraded “AI Agent 2.0” will enhance pharmaceutical logistics and online healthcare services. This partnership is a game-changer. It combines Fangzhou’s healthcare expertise with Tencent’s technological prowess, paving the way for smarter, more efficient solutions.

DeepSeek’s architecture is designed for scalability and efficiency. Its Mixture-of-Experts (MoE) model ensures that Fangzhou can handle increased demand without compromising on performance. Moreover, the private deployment of DeepSeek ensures compliance with data privacy regulations, a critical factor in today’s digital landscape.

The deployment of “AI Agent 2.0” signifies a milestone in Fangzhou’s journey. This system focuses on two core areas: patient services and physician workflows. By enhancing these areas, Fangzhou aims to deliver a seamless experience for both patients and healthcare providers.

Fangzhou’s trajectory is not just about numbers; it’s about impact. The company is dedicated to improving the lives of chronic disease patients through tailored medical care and precision medicine. With 49.2 million registered users and 223,000 physicians on its platform, Fangzhou is well-positioned to lead the charge in AI-driven healthcare.

As Fangzhou continues to innovate and expand, it stands as a testament to the potential of technology in healthcare. The company’s commitment to AI-powered solutions is not just a strategy; it’s a vision for the future. In a world where healthcare is increasingly digital, Fangzhou is at the forefront, shaping the landscape of chronic disease management in China.



In conclusion, Fangzhou Inc. is more than a healthcare provider; it’s a pioneer. With its strong financial performance, strategic partnerships, and unwavering focus on innovation, the company is set to redefine the healthcare experience for millions. The future is bright for Fangzhou, and its journey is one to watch closely.